DK0565377T3 - Terapeutiske midler til behandling af Parkinsons sygdom - Google Patents
Terapeutiske midler til behandling af Parkinsons sygdomInfo
- Publication number
- DK0565377T3 DK0565377T3 DK93302780.7T DK93302780T DK0565377T3 DK 0565377 T3 DK0565377 T3 DK 0565377T3 DK 93302780 T DK93302780 T DK 93302780T DK 0565377 T3 DK0565377 T3 DK 0565377T3
- Authority
- DK
- Denmark
- Prior art keywords
- group
- parkinson
- disease
- treatment
- therapeutic agents
- Prior art date
Links
- 208000018737 Parkinson disease Diseases 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title abstract 2
- 229940124597 therapeutic agent Drugs 0.000 title abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000004432 carbon atom Chemical group C* 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 abstract 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/12—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1, 3, and 7, e.g. caffeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP8711592 | 1992-04-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK0565377T3 true DK0565377T3 (da) | 1998-03-16 |
Family
ID=13905960
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK93302780.7T DK0565377T3 (da) | 1992-04-08 | 1993-04-08 | Terapeutiske midler til behandling af Parkinsons sygdom |
Country Status (11)
| Country | Link |
|---|---|
| EP (1) | EP0565377B1 (fr) |
| JP (1) | JP2613352B2 (fr) |
| AT (1) | ATE161723T1 (fr) |
| BR (1) | BR1100636A (fr) |
| CA (1) | CA2093403C (fr) |
| DE (1) | DE69316067T2 (fr) |
| DK (1) | DK0565377T3 (fr) |
| ES (1) | ES2112386T3 (fr) |
| GR (1) | GR3026233T3 (fr) |
| HK (1) | HK1001835A1 (fr) |
| NO (1) | NO303265B1 (fr) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0585464A4 (fr) * | 1992-02-19 | 1994-03-21 | Yukio Ishida | Riz absorbant fortement l'eau, procede de fabrication de ce riz et utilisation correspondante. |
| DE69331843T2 (de) * | 1992-07-08 | 2002-09-26 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine-Derivate als Antidepressiva |
| JP2613355B2 (ja) * | 1992-09-28 | 1997-05-28 | 協和醗酵工業株式会社 | パーキンソン氏病治療剤 |
| AU6781194A (en) * | 1993-05-03 | 1994-11-21 | United States Of America, Represented By The Secretary, Department Of Health And Human Services, The | 8-substituted 1,3,7-trialkyl-xanthine derivatives as a2-selective adenosine receptor antagonists |
| DE69430747T2 (de) * | 1993-07-28 | 2003-03-06 | Aventis Pharma Ltd., West Malling | Verbindungen als pde iv und tnf inhibitoren |
| AU1823895A (en) * | 1994-02-23 | 1995-09-11 | Kyowa Hakko Kogyo Co. Ltd. | Xanthine derivative |
| CA2262578A1 (fr) * | 1996-08-07 | 1998-02-12 | Kunio Ito | Emulsion grasse contenant un derive de xanthine |
| US6727259B2 (en) | 1997-09-05 | 2004-04-27 | Kyowa Hakko Kogyo Co., Ltd. | Remedial agent for neural degeneration |
| AU2002343604C1 (en) | 2001-10-30 | 2009-09-17 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| RU2367442C2 (ru) | 2003-04-25 | 2009-09-20 | Новокардия, Инк. | Способ нормализации мочеиспускания при нарушении функции почек |
| CN101906106A (zh) | 2003-09-18 | 2010-12-08 | 康福玛医药公司 | 作为hsp90-抑制剂的新的杂环化合物 |
| ES2532479T3 (es) | 2004-01-28 | 2015-03-27 | Kyowa Hakko Kirin Co., Ltd. | Agentes para el tratamiento de la migraña |
| AU2006230447A1 (en) * | 2005-03-30 | 2006-10-05 | Conforma Therapeutics Corporation | Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors |
| EP1928414A2 (fr) * | 2005-04-22 | 2008-06-11 | Novacardia, Inc. | Production d'emulsions pour injection intraveineuse de compositions pharmaceutiques insolubles dans l'eau |
| KR20090094465A (ko) * | 2006-12-22 | 2009-09-07 | 슈바르츠 파르마 악티엔게젤샤프트 | 선택적 ａ2ａ 수용체 안타고니스토로서의 8-알키닐잔틴 유도체 |
| US7994357B2 (en) * | 2009-04-03 | 2011-08-09 | Naturewise Biotech & Medicals Corporation | Cinamic compounds and derivatives therefrom for the inhibition of histone deacetylase |
| WO2020125779A1 (fr) * | 2018-12-21 | 2020-06-25 | Sunshine Lake Pharma Co., Ltd. | Dérivés de styryl xanthine substitués en position 8 et leurs utilisations |
| CN111333648B (zh) * | 2019-04-24 | 2021-05-11 | 东莞市东阳光新药研发有限公司 | 8-取代的芳香环乙烯基黄嘌呤衍生物及其用途 |
| CN110041331B (zh) * | 2019-05-17 | 2020-08-07 | 广东东阳光药业有限公司 | 苯乙烯基黄嘌呤衍生物及其用途 |
| CN112409360B (zh) * | 2019-08-22 | 2022-12-23 | 广东东阳光药业有限公司 | 杂芳基乙烯基黄嘌呤衍生物及其用途 |
| WO2021093701A1 (fr) * | 2019-11-11 | 2021-05-20 | Sunshine Lake Pharma Co., Ltd. | Dérivés de styryl xanthine substitués en position 8 et leurs utilisations |
| CN111072663B (zh) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 |
| CN111018856B (zh) * | 2019-12-12 | 2021-10-01 | 广东东阳光药业有限公司 | 8-取代的苯乙烯基黄嘌呤衍生物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA929519A (en) * | 1969-07-30 | 1973-07-03 | Schweiss Dieter | Xanthine compounds and means for obtaining the same |
| DE3843117A1 (de) * | 1988-12-22 | 1990-06-28 | Boehringer Ingelheim Kg | Neue xanthinderivate mit adenosin-antagonistischer wirkung |
| GB8906792D0 (en) * | 1989-03-23 | 1989-05-10 | Beecham Wuelfing Gmbh & Co Kg | Treatment and compounds |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| FR2665636B1 (fr) * | 1990-08-10 | 1994-10-07 | Adir | Utilisation d'un derive de la trimethyl-1,3,7 xanthine pour le traitement des troubles de la memoire, des troubles intellectuels de la senescence et de la maladie d'alzheimer. |
| WO1992006976A1 (fr) * | 1990-10-18 | 1992-04-30 | Kyowa Hakko Kogyo Co., Ltd. | Derive de xanthine |
-
1993
- 1993-04-05 CA CA002093403A patent/CA2093403C/fr not_active Expired - Lifetime
- 1993-04-06 NO NO931317A patent/NO303265B1/no not_active IP Right Cessation
- 1993-04-08 DK DK93302780.7T patent/DK0565377T3/da active
- 1993-04-08 JP JP5081953A patent/JP2613352B2/ja not_active Expired - Fee Related
- 1993-04-08 EP EP93302780A patent/EP0565377B1/fr not_active Expired - Lifetime
- 1993-04-08 AT AT93302780T patent/ATE161723T1/de not_active IP Right Cessation
- 1993-04-08 ES ES93302780T patent/ES2112386T3/es not_active Expired - Lifetime
- 1993-04-08 DE DE69316067T patent/DE69316067T2/de not_active Expired - Lifetime
-
1997
- 1997-05-13 BR BR1100636-6A patent/BR1100636A/pt active IP Right Grant
-
1998
- 1998-02-04 HK HK98100812A patent/HK1001835A1/xx not_active IP Right Cessation
- 1998-02-25 GR GR980400413T patent/GR3026233T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2093403A1 (fr) | 1993-10-09 |
| BR1100636A (pt) | 2000-04-18 |
| NO931317L (no) | 1993-10-11 |
| HK1001835A1 (en) | 1998-07-10 |
| ES2112386T3 (es) | 1998-04-01 |
| CA2093403C (fr) | 1999-08-10 |
| JPH0616559A (ja) | 1994-01-25 |
| NO931317D0 (no) | 1993-04-06 |
| GR3026233T3 (en) | 1998-05-29 |
| DE69316067D1 (de) | 1998-02-12 |
| JP2613352B2 (ja) | 1997-05-28 |
| EP0565377A1 (fr) | 1993-10-13 |
| EP0565377B1 (fr) | 1998-01-07 |
| DE69316067T2 (de) | 1998-07-02 |
| ATE161723T1 (de) | 1998-01-15 |
| NO303265B1 (no) | 1998-06-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK0565377T3 (da) | Terapeutiske midler til behandling af Parkinsons sygdom | |
| DK0590919T3 (da) | Terapeutiske midler mod Parkinsons sygdom | |
| DE69418704D1 (de) | Anthranilsäure derivate | |
| DE69130120D1 (de) | Derivate von zyklischen Amiden | |
| ATE216584T1 (de) | Xanthine-derivate als antidepressiva | |
| ATE232531T1 (de) | Heterobizyklische derivate | |
| DE69221794D1 (de) | 3-benzyliden-1-carbamoyl-2-pyrrolidon-analoga | |
| HUT68856A (en) | Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions | |
| ATE34976T1 (de) | Arylcyclobutylalkylamine und ihre verwendung als antidepressive arzneimittel. | |
| KR910009672A (ko) | 피리다진 유도체, 이의 제조방법 및 이것을 함유하는 약학 조성물 | |
| FI884088A0 (fi) | Foerfarande foer framstaellning av 17-substituerade androsta-1,4-dien-3-onderivat. | |
| DE69230498D1 (de) | 2-Pyrazinylethylamin-Derivate und ihre Verwendung als Arzneimittel. | |
| DE69110217D1 (de) | Derivate der Kaffeinsäure und sie enthaltende pharmazeutische Zusammensetzungen. | |
| DE69626624D1 (de) | Medikamente gegen trhombocytopenie | |
| DK0461012T3 (da) | Derivater af ((1-arylpyrrolidin-2-yl)methyl)piperazin, fremstillingen heraf og deres terapeutiske anvendelse | |
| FR2694557B1 (fr) | Dérivés de tétrahydronaphtalène, leur préparation, et leur application en thérapeutique. |